PMID- 16469323
OWN - NLM
STAT- MEDLINE
DCOM- 20070130
LR  - 20131121
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 189
IP  - 2
DP  - 2006 Dec
TI  - Different effects of oral conjugated estrogen and transdermal estradiol on 
      arterial stiffness and vascular inflammatory markers in postmenopausal women.
PG  - 436-42
AB  - AIMS: We compared the effects of oral conjugated equine estrogen (CEE) therapy 
      and transdermal estradiol therapy on pulse wave velocity (PWV) and circulating 
      levels of vascular inflammatory markers in postmenopausal women and we also 
      explored the interrelationship between the change in PWV and the changes in 
      vascular inflammatory markers. METHODS AND RESULTS: In a randomized 12-month 
      trial, 28 postmenopausal women received a continuous oral CEE plus cyclic 
      medroxyprogesterone acetate (MPA), 28 received a continuous transdermal estradiol 
      patch plus cyclic MPA, and 27 did not receive either therapy. In each subject, we 
      measured the brachial-ankle PWV (baPWV) using an automated device, the blood 
      pressure, and the circulating levels of vascular inflammatory markers (C-reactive 
      protein [CRP], cell adhesion molecules [CAMs], monocyte chemoattractant protein-1 
      [MCP-1], and matrix metalloproteinase [MMP-9]) before and 12 months after the 
      start of the study. Oral CEE therapy did not change the baPWV but significantly 
      increased the CRP and MMP-9 levels (P<0.05, each) and significantly decreased the 
      CAMs and MCP-1 levels (P<0.05, each). Transdermal estradiol therapy significantly 
      decreased the baPWV, and the CAMs and MCP-1 levels (P<0.05, each) but had no 
      effect on the CRP or MMP-9 levels. No significant changes were seen in the 
      control group. The blood pressures of the subjects remained unchanged. In the 
      transdermal estradiol group, the change in baPWV was not significantly correlated 
      with the changes in vascular inflammatory markers. CONCLUSION: Transdermal 
      estradiol, but not oral CEE therapy, may have antiatherosclerotic effects by 
      improving arterial stiffness. The reduction in baPWV may contribute to the direct 
      effect of estrogen, but not to the decrease in estrogen-induced vascular 
      inflammatory markers.
FAU - Sumino, Hiroyuki
AU  - Sumino H
AD  - Department of Medicine and Biological Science, Gunma University Graduate School 
      of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan. 
      suminoh@med.gunmma-u.ac.jp
FAU - Ichikawa, Shuichi
AU  - Ichikawa S
FAU - Kasama, Shu
AU  - Kasama S
FAU - Takahashi, Takashi
AU  - Takahashi T
FAU - Kumakura, Hisao
AU  - Kumakura H
FAU - Takayama, Yoshiaki
AU  - Takayama Y
FAU - Kanda, Tsugiyasu
AU  - Kanda T
FAU - Kurabayashi, Masahiko
AU  - Kurabayashi M
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20060215
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Estrogens)
RN  - 0 (Estrogens, Conjugated (USP))
RN  - 4TI98Z838E (Estradiol)
SB  - IM
MH  - Administration, Cutaneous
MH  - Administration, Oral
MH  - Aged
MH  - Atherosclerosis/blood/physiopathology/*prevention & control
MH  - Blood Pressure/drug effects
MH  - Estradiol/*administration & dosage/therapeutic use
MH  - Estrogens/*administration & dosage/therapeutic use
MH  - Estrogens, Conjugated (USP)/*administration & dosage/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Inflammation/*blood/physiopathology/prevention & control
MH  - Middle Aged
MH  - *Postmenopause
MH  - Treatment Outcome
MH  - Vascular Resistance/*drug effects
EDAT- 2006/02/14 09:00
MHDA- 2007/01/31 09:00
CRDT- 2006/02/14 09:00
PHST- 2005/06/30 00:00 [received]
PHST- 2005/12/14 00:00 [revised]
PHST- 2005/12/31 00:00 [accepted]
PHST- 2006/02/14 09:00 [pubmed]
PHST- 2007/01/31 09:00 [medline]
PHST- 2006/02/14 09:00 [entrez]
AID - S0021-9150(06)00002-5 [pii]
AID - 10.1016/j.atherosclerosis.2005.12.030 [doi]
PST - ppublish
SO  - Atherosclerosis. 2006 Dec;189(2):436-42. doi: 
      10.1016/j.atherosclerosis.2005.12.030. Epub 2006 Feb 15.